Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you! All valid points. I have mention that it is important for STRENGTH trial to show RRR, at least enough for some benefit, 8% would be fine, since it surley raised EPA blood serum levels. But not enough to produce the higher levels of RRR seen in REDUCE-IT trial. While still validating O3 EPA trials, yet not enough to compete with Vascepa. This will close the chapter for DHA as far as a CVD risk reducer.
Many here agree with me!
I took the liberty and sent pr@amarincorp.com a review of the new website! I hope the remove it soon - it's embarrassing!
I think IR needs to hear from a few stock holders, regarding the poor quality of the website!
My thoughts exactly..
Yes I was talking about the artwork...Not a girl though, BioChica is my older Daughter.
Pyre where do you stand regarding DHA? :>) Haaaa Haaa Haa Ha. I just can't stop laughing.
The hearts look like a four year old drew them...and yes it is that bad.
The truth about Amarins "https://truetoyourheart.com/" website. The design is horrible - graphics design grade F. This was a rush job.
Was this a contest offered by J.T. for 5th graders to design a website for Amarin?
:>) We will have to see how will it did, as far as constipation goes!
Yes, Their luck has certainly turned around over the last couple of years.
Steven Nissen, chief academic officer of the Heart and Vascular Institute in Cleveland, Ohio, who chaired the trial, said his team was “disappointed” with the result.
The company said the results of the trials would not affect the drug’s use in treating severe hypertriglyceridaemia.
Really? How are they going use EPANOVA to treat hypertriglyceridaemia under the threat of patent infringement.
When are they going to stop focusing on Triglycerides?
I think it is important to wait and see what the results have to show us, i.e. the blood levels of EPA in the trial should give us a clue. A comparison between the two trials can be made. Hopefully see some actual numbers soon and what really went wrong.
AZN can not afford AMRN.
Run away would be my best advice.
Yes now I'm getting interested again...So long to get to this stage.
Actually they are not handing over approvals anymore for drugs that lower LDL-C, without CVOT. Due to a number of drugs that failed CVOT's even though they lowered LDL-C.
Hey buddy - Triglyceride lowering is incidental! Anyone interest in this drug should know that.
Better yet! Cantor Fitzgerald confirmed with United Health this was old news and Cantor Fitzgerald believes the reimbursement situation with UnitedHealth could get better quickly, now that Vascepa has a broad label.
Todays news was noise. Overweight rating $35 target price.
Yes I seen quite a few calls for March 20 options. Not sure if it means anything.
Thanks, just what I thought. Why i’m glad we switched back to Cigna. No qualification for Trig levels CoPay $10, I can live with. I’m sure with update to formulary this may come down.
You would think!
Probably still have a qualifier of Triglycerides greater than 499.
I'm a little peeved with J.T's release of spending guidance. Why even do this? Revenue guidance is all that is needed, maybe at this point not even that. He setup the share holders, while all the insiders(B.M's) are executing/selling options hand over fist. They seem to know this stock is going south for the first half of the year. Food for thought!
The updates EPS for the first half has dropped further into negative territory I noticed on ETRADE.
Yes $8 is a stretch.
Analyst's not happy with spending projections. This is one thing that could spoil success J.T. spending pace could outpace sales for the year.
Amarin spend guidance significantly above expectations, says Oppenheimer Oppenheimer analyst Leland Gershell says Amarin's updated guidance for an operating expenses increase of $200M-$250M relative to 2019 levels is significantly higher than Street's consensus of an increase of $150M. While its 2020 revenue guidance of $650M to $700M was reiterated, in order to break even on cash flow Amarin requires $150M in revenue per quarter without factoring inventory build and $200M revenue per quarter including inventory build, Gershell tells investors in a research note. The analyst concludes that $700M in 2020 revenue is required to break even, meaning Vascepa sales would need to beat guidance to be cash flow positive. Further, Gershell cautions investors that Amarin's spend in Q1 and 2020 will likely be heavier than expectations, diminishing its profitability. The analyst reiterates an Underperform rating on the shares with an $8 price target. The stock in premarket trading is down 28c to $19.80.
Read more at:
https://thefly.com/landingPageNews.php?id=3014590
We dropped United health Care and moved back to Cigna. Our company not happy with UHC.
NK4000 DO you have any info regarding the trials or links? Yes this is very interesting.
Never the less, this statement from Cramer should draw more retail longs into the picture.
He's been selling through out the year. It seems our board members have no faith! I think most of us longs have shown more faith in the stock and company.
1/3/20 Zakrzewski Joseph S
Director Sale 300,000 20.94 – 20.94 84,547 $6.3 M
Zakrzewski Joseph S
Director Exercise of Options 300,000 3.40 – 3.40 84,547 $1.0 M
Zakrzewski Joseph S
Director Exercise of Options 100,000 9.00 – 9.00 84,547 $900.0 K
Zakrzewski Joseph S
Director Sale 100,000 25.83 – 25.83 84,547 $2.6 M
7/5/19 Zakrzewski Joseph S
Director Sale 100,000 23.82 – 23.82 84,547 $2.4 M
Zakrzewski Joseph S
Director Exercise of Options 100,000 9.00 – 9.00 84,547 $900.0 K
6/18/19 Zakrzewski Joseph S
Director Sale 100,000 19.02 – 19.02 84,547 $1.9 M
Zakrzewski Joseph S
Director Exercise of Options 100,000 3.40 – 3.40 84,547 $340.0 K
2/22/19 Zakrzewski Joseph S
Director Sale 180,625 19.90 – 19.90 84,547 $3.6 M
Zakrzewski Joseph S
Director Exercise of Options 180,625 8.10 – 8.86 84,547 $1.6 M
Zakrzewski Joseph S
Director Exercise of Options 200,000 3.40 – 3.40 84,547 $680.0 K
1/10/19 Zakrzewski Joseph S
Director Sale 200,000 16.00 – 17.96 84,547 $3.4 M
Zacks for example: Negative article
Focus on March 20th Puts
Yet Call volume far exceeds PUT volume for March 20th Options.
Share are selling like hot cakes!
It’s not just about how much you sell, but how much profit you earn.
Currently they have not broken even. Let’s hope they can control spending and start seeing a quarterly positive EPS. Now it’s up to J.T. to execute a solid business plan.
The proof that this is a scam in in your court - please post facts.
So far, you are fake news!
I think we did better!
Yea you probably need glasses. But who really cares about these swings in price, minor movements most longs don’t pay attention too.
To much noise from marketeers who really don’t get it. Analysts with with no clue.
Hardly -6.73% and yesterday was around the same. It dropped more when Oppenheimer’s down graded AMRN stock. They showed us, the marketeers really are clueless.
Last Price
$21.34
Today’s Change
-1.54 (-6.73%)
Bloodbath? Slightly hysterical!